Evidence map›Paper›PMID 20980099›Full record

ArticleCancer letters2011

ZEB1-responsive genes in non-small cell lung cancer.

Robert M Gemmill, Joëlle Roche, Vincent A Potiron, Patrick Nasarre, Michael Mitas, Chris D Coldren, Barbara A Helfrich, Elizabeth Garrett-Mayer, Paul A Bunn, Harry A Drabkin

Registry-linked trialAbstract read
In one paragraph

Article in Cancer letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01480141 (A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib), which is not on this map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01480141 phase2withdrawnnot on this mapstarted 2012, after this paper: background citation

A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC

TypeinterventionalSponsorMedical University of South CarolinaRan2012 to 2012Enrolled0ConditionsLung CancerArmsBIBW 2992 (Afatinib)
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 180 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Opioid System and Epithelial-Mesenchymal Transition.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Resistance to mutant KRASExperimental cell research · 2022
    Article
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Robert M GemmillDivision of Hematology-Oncology, Department of Medicine and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Joëlle Roche
Vincent A Potiron
Patrick Nasarre
Michael Mitas
Chris D Coldren
Barbara A Helfrich
Elizabeth Garrett-Mayer
Paul A Bunn
Harry A Drabkin
Medical University of South Carolina · USMUSC Hollings Cancer Center · USUniversity of Colorado Cancer Center · USUniversity of Colorado Denver · US

Funding

Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8M
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
NCI NIH HHS CA138313NCI NIH HHS CA58187NCI NIH HHS P30 CA138313NCI NIH HHS P50 CA058187
6 · The paper itself

Abstract

The epithelial to mesenchymal transition (EMT) is a developmental process enabling epithelial cells to gain a migratory mesenchymal phenotype. In cancer, this process contributes to metastases; however the regulatory signals and mechanistic details are not fully elucidated. Here, we sought to identify the subset of genes regulated in lung cancer by ZEB1, an E-box transcriptional repressor known to induce EMT. Using an Affymetrix-based expression database of 38 non-small cell lung cancer (NSCLC) cell lines, we identified 324 genes that correlated negatively with ZEB1 and 142 that were positively correlated. A mesenchymal gene pattern (low E-cadherin, high Vimentin or N-cadherin) was significantly associated with ZEB1 and ZEB2, but not with Snail, Slug, Twist1 or Twist2. Among eight genes selected for validation, seven were confirmed to correlate with ZEB1 by quantitative real-time RT-PCR in a series of 22 NSCLC cell lines, either negatively (CDS1, EpCAM, ESRP1, ESRP2, ST14) or positively (FGFR1, Vimentin). In addition, over-expression or knockdown of ZEB1 led to corresponding changes in gene expression, demonstrating that these genes are also regulated by ZEB1, either directly or indirectly. Of note, the combined knockdown of ZEB1 and ZEB2 led to apparent synergistic responses in gene expression. Furthermore, these responses were not restricted to artificial settings, since most genes were similarly regulated during a physiologic induction of EMT by TGF-β plus EGF. Finally, the absence of ST14 (matriptase) was linked to ZEB1 positivity in lung cancer tissue microarrays, implying that the regulation observed in vitro applies to the human disease. In summary, this study identifies a new set of ZEB-regulated genes in human lung cancer cells and supports the hypothesis that ZEB1 and ZEB2 are key regulators of the EMT process in this disease.

Indexed as

Blotting, WesternCadherinsCarcinoma, Non-Small-Cell LungCell Line, TumorEpithelial-Mesenchymal TransitionHomeodomain ProteinsHumansLung NeoplasmsRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionSerine EndopeptidasesTranscription FactorsZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2CadherinsHomeodomain ProteinsRepressor ProteinsSerine EndopeptidasesST14 protein, humanTranscription FactorsZEB1 protein, humanZEB2 protein, humanZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2

Identifiers

PMID20980099
PMCPMC3337721
OpenAlexW2142426658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.